Buy them and shut them down
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Health care investor Kevin Tang buys “zombie” biotechs to shut them down. It’s a counterintuitive, but ingenious solution to the sector’s intractable problem covered in last week’s newsletter. Tang’s disposal service is not a […]
Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars. That’s when we’ll get the first look at data from a pivotal clinical trial of anito-cel, […]
How to Ride the Biotech Roller Coaster
With stocks starting to price in interest-rate cuts next year, the biotech sector has emerged as a winner for investors seeking riskier bets with more distant payoffs. But investing in this industry is tricky because biotech is a sector of haves and have-nots. While every industry has its winners and losers, the gap in biotech […]